




RealRate

# PHARMACEUTICAL 2021

Statera Biopharma Inc.  
Rank 231 of 402





RealRate

# PHARMACEUTICAL 2021

## Statera Biopharma Inc. Rank 231 of 402



The relative strengths and weaknesses of Statera Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Statera Biopharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 48% points. The greatest weakness of Statera Biopharma Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 119% points.

The company's Economic Capital Ratio, given in the ranking table, is 75%, being 28% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	2,314
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	305
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-78
Other Expenses	0
Other Liabilities	0
Other Net Income	149
Other Revenues	263
Property and Equipment	3.7
Research and Development	691
Selling, General and Administrative Expense	2,158

Output Variable	Value in 1000 USD
Assets	2,318
Liabilities	305
Expenses	2,849
Revenues	263
Stockholders Equity	2,013
Net Income	-2,438
Comprehensive Net Income	-2,477
Economic Capital Ratio	75%